Skip to main content
. 2022 Dec;17(12):1730–1741. doi: 10.2215/CJN.03790322

Figure 3.

Figure 3.

ICER (US dollars per QALY) evolution over time in the United Kingdom, Germany, and Spain. Negative ICERs represent scenarios where dapagliflozin is considered the dominant treatment option (i.e., a lower cost and higher QALYs compared with placebo).